Aster DM Healthcare Ltd
Aster DM Healthcare Limited is one of the largest integrated private healthcare service providers operating in GCC (Gulf Cooperation Council) countries and an emerging player in India. With an inherent emphasis on clinical excellence, it is one of the few entities in the world with a strong presence across primary, secondary, tertiary and quaternary healthcare. [1]
- Market Cap ₹ 20,180 Cr.
- Current Price ₹ 404
- High / Low ₹ 422 / 201
- Stock P/E 62.2
- Book Value ₹ 87.6
- Dividend Yield 0.00 %
- ROCE 9.21 %
- ROE 11.0 %
- Face Value ₹ 10.0
Pros
- Company's median sales growth is 16.4% of last 10 years
Cons
- Stock is trading at 4.37 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 10.3% over last 3 years.
- Company might be capitalizing the interest cost
- Promoters have pledged 98.9% of their holding.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Healthcare Industry: Healthcare
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1,922 | 2,871 | 3,876 | 5,250 | 5,931 | 6,721 | 7,963 | 8,652 | 8,608 | 10,253 | 11,933 | 12,986 | |
1,660 | 2,421 | 3,370 | 4,805 | 5,582 | 6,089 | 6,886 | 7,187 | 7,506 | 8,720 | 10,307 | 11,282 | |
Operating Profit | 261 | 451 | 506 | 445 | 349 | 632 | 1,077 | 1,465 | 1,103 | 1,533 | 1,626 | 1,705 |
OPM % | 14% | 16% | 13% | 8% | 6% | 9% | 14% | 17% | 13% | 15% | 14% | 13% |
11 | 19 | 23 | 25 | 453 | 177 | -155 | -158 | 53 | 51 | 79 | -13 | |
Interest | 45 | 48 | 79 | 189 | 371 | 204 | 205 | 391 | 334 | 307 | 390 | 384 |
Depreciation | 76 | 111 | 144 | 243 | 322 | 298 | 306 | 586 | 618 | 641 | 780 | 861 |
Profit before tax | 151 | 310 | 306 | 38 | 108 | 308 | 410 | 330 | 205 | 637 | 535 | 447 |
Tax % | 4% | 9% | 11% | 78% | 10% | 8% | 10% | 5% | 13% | 6% | 11% | |
149 | 284 | 272 | 8 | 98 | 282 | 367 | 315 | 178 | 601 | 475 | 346 | |
EPS in Rs | 7.26 | 4.69 | 7.00 | 0.20 | 2.52 | 5.32 | 6.59 | 5.54 | 2.96 | 10.53 | 8.51 | 5.69 |
Dividend Payout % | 0% | 35% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 20% |
5 Years: | 12% |
3 Years: | 11% |
TTM: | 20% |
Compounded Profit Growth | |
---|---|
10 Years: | 16% |
5 Years: | 22% |
3 Years: | -1% |
TTM: | -34% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 20% |
3 Years: | 30% |
1 Year: | 65% |
Return on Equity | |
---|---|
10 Years: | 10% |
5 Years: | 12% |
3 Years: | 10% |
Last Year: | 11% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 125 | 375 | 389 | 403 | 403 | 505 | 505 | 497 | 497 | 500 | 500 | 500 |
Reserves | 654 | 536 | 1,096 | 17 | 1,472 | 2,327 | 2,709 | 2,775 | 2,875 | 3,080 | 3,574 | 3,874 |
Preference Capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 374 | 374 | |
505 | 886 | 1,091 | 3,321 | 2,758 | 2,352 | 2,788 | 5,605 | 4,804 | 4,907 | 5,700 | 5,995 | |
856 | 1,097 | 1,834 | 2,003 | 2,171 | 2,296 | 2,926 | 3,528 | 3,444 | 4,035 | 5,062 | 5,340 | |
Total Liabilities | 2,140 | 2,894 | 4,409 | 5,743 | 6,804 | 7,479 | 8,928 | 12,405 | 11,620 | 12,521 | 14,836 | 15,708 |
872 | 1,087 | 2,237 | 2,507 | 3,520 | 3,738 | 4,289 | 7,124 | 6,749 | 7,009 | 9,052 | 9,441 | |
CWIP | 185 | 357 | 197 | 358 | 290 | 402 | 550 | 736 | 934 | 998 | 279 | 395 |
Investments | 6 | 7 | 3 | 39 | 32 | 38 | 22 | 34 | 63 | 45 | 80 | 36 |
1,077 | 1,442 | 1,972 | 2,839 | 2,962 | 3,302 | 4,067 | 4,511 | 3,874 | 4,470 | 5,425 | 5,835 | |
Total Assets | 2,140 | 2,894 | 4,409 | 5,743 | 6,804 | 7,479 | 8,928 | 12,405 | 11,620 | 12,521 | 14,836 | 15,708 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|
236 | 203 | 361 | 537 | 601 | 1,223 | 1,569 | 1,314 | 1,834 | |||
-439 | -775 | -1,136 | -522 | -702 | -658 | -333 | -563 | -951 | |||
203 | 578 | 654 | 46 | 134 | -675 | -1,116 | -686 | -817 | |||
Net Cash Flow | -1 | 5 | -122 | 61 | 33 | -110 | 120 | 65 | 66 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 95 | 86 | 83 | 93 | 79 | 84 | 93 | 100 | 86 | 72 | 71 |
Inventory Days | 84 | 71 | 93 | 92 | 102 | 111 | 110 | 138 | 122 | 129 | 135 |
Days Payable | 213 | 176 | 178 | 187 | 151 | 150 | 153 | 303 | 290 | 267 | 309 |
Cash Conversion Cycle | -34 | -18 | -2 | -1 | 30 | 45 | 50 | -65 | -83 | -66 | -102 |
Working Capital Days | 82 | 61 | 69 | 68 | 57 | 59 | 57 | 40 | 38 | 40 | 32 |
ROCE % | 18% | 14% | 6% | 1% | 7% | 13% | 12% | 6% | 10% | 9% |
Documents
Announcements
-
Video/Audio Recording Of Investors Conference Call
1d - The investors conference call of the Company post Q2 FY 2023-24 Results on segregation of GCC & India was held today, November 29, 2023 and …
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
2d - The Investors Conference Call post Q2 FY 2023-24 Results with analysts/ Investors originally scheduled on Tuesday, November 28, 2023, at 05:30 PM (IST) has been …
-
Announcement under Regulation 30 (LODR)-Investor Presentation
2d - With reference to the captioned subject, please find enclosed the investor presentation on Corporate Restructuring.
-
Corrigendum In Respect Of Outcome Of The Meeting
2d - The consideration receivable from the transaction should be read as USD 1.001 Billion instead of USD 1.01 Billion in the cover letter as well as …
-
Announcement under Regulation 30 (LODR)-Memorandum of Understanding /Agreements
2d - In relation to the captioned subject we hereby inform you that, the Board of the Company has its meeting held on November 28, 2023 approved …
Annual reports
Concalls
-
Nov 2023TranscriptNotesPPT
-
Nov 2023TranscriptNotesPPT
-
Aug 2023Transcript PPT
-
Jun 2023Transcript PPT REC
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022TranscriptPPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Sep 2021Transcript PPT
-
Aug 2021Transcript PPT
-
Jun 2021TranscriptPPT
-
Mar 2021TranscriptPPT
-
Feb 2021Transcript PPT
-
Dec 2020Transcript PPT
-
Nov 2020TranscriptPPT
-
Aug 2020Transcript PPT
-
Jun 2020Transcript PPT
-
Jun 2020TranscriptNotesPPT
-
Feb 2020Transcript PPT
-
Feb 2020TranscriptNotesPPT
-
Nov 2019Transcript PPT
-
Sep 2019Transcript PPT
-
Aug 2019Transcript PPT
-
Jun 2019Transcript PPT
-
May 2019TranscriptPPT
-
Mar 2019TranscriptPPT
-
Feb 2019Transcript PPT
-
Nov 2018Transcript PPT
-
Aug 2018Transcript PPT
-
Jun 2018Transcript PPT
Network
The Co. is an emerging player in India through its network of 27 hospitals, 120 clinics, 371 pharmacies, 14 labs & 100 patient experience centres as on March 31, 2022. [1]